Corrigendum to Glycobiology of neuroblastoma: Impact on tumor behavior, prognosis, and therapeutic strategies [Front Oncol, 4 (2014) 114] DOI: 10.3389/fonc.2014.00114;Glycobiology of neuroblastoma: Impact on tumor behavior, prognosis, and therapeutic strategies

Frontiers in Oncology

Volumn 4 MAY, Issue , 2014, Pages

  Berois, Nora ^a   Osinaga, Eduardo ^a,b  

^a INSTITUT PASTEUR DE MONTEVIDEO   (Uruguay)

^b DEPARTAMENTO DE BIOQUÍMICA   (Uruguay)

Author keywords

Galectin 1; Gangliosides; Glycosylation; Glycosyltransferases; Immunotherapy; Neuroblastoma; Polysialic acid

Indexed keywords

ALPHA 1,3(6) MANNOSYLGLYCOPROTEIN BETA 1,6 N ACETYLGLUCOSAMINYLTRANSFERASE; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; BETA 1, 3 N ACETYLGLUCOSAMINYLTRANSFERASE 3; BETA 1, 4 N ACETYLGALACTOSAMINYLTRANSFERASE 3; GALECTIN 1; GANGLIOSIDE; GANGLIOSIDE GD2; GD2 ANTIBODY 3F8; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; ISOTRETINOIN; MONOCLONAL ANTIBODY 14.G2A; N ACETYLGLUCOSAMINYLTRANSFERASE; NERVE CELL ADHESION MOLECULE; POLYSIALIC ACID; RETINOIC ACID; SIALYLTRANSFERASE; TUMOR MARKER; UDP POLYPEPTIDE GALNAC TRANSFERASE; UDP POLYPEPTIDE GALNAC TRANSFERASE 9; UNCLASSIFIED DRUG;

AGGRESSIVENESS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CLINICAL TRIAL (TOPIC); GLYCOBIOLOGY; HUMAN; N LINKED GLYCOSYLATION; NEUROBLASTOMA; NONHUMAN; O LINKED GLYCOSYLATION; PROTEIN CARBOHYDRATE INTERACTION; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; REVIEW; TREATMENT OUTCOME;

EID: 84904655102     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00193     Document Type: Erratum

References (184)

1. Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am (2010) 24:65-86. doi: 10.1016/j.hoc.2009.11.011
2. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer (2003) 3:203-16. doi:10.1038/nrc1014
3. Navarro S, Piqueras M, Villamón E, Yáñez Y, Balaguer J, Cañete A, et al. New prognostic markers in neuroblastoma. Expert Opin Med Diagn (2012) 6:555-67. doi:10.1517/17530059.2012.704018
4. Shimada H, Umehara S, Monobe Y, Hachitanda Y, Nakagawa A, Goto S, et al. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer (2001) 92:2451-61. doi:10.1002/1097-0142(20011101)92:9<2451::AID-CNCR1595>3.0.CO;2-S
5. Bagatell R, Beck-Popovic M, London WB, Zhang Y, Pearson AD, Matthay KK, et al. Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. J Clin Oncol (2009) 27:365-70. doi:10.1200/JCO.2008.17.9184
6. Carén H, Kryh H, Nethander M, Sjöberg RM, Träger C, Nilsson S, et al. High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci U S A (2010) 107:4323-8. doi:10.1073/pnas.0910684107
7. Rubie H, De Bernardi B, Gerrard M, Canete A, Ladenstein R, Couturier J, et al. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. J Clin Oncol (2011) 29:449-55. doi:10.1200/JCO.2010.29.5196
8. Canete A, Gerrard M, Rubie H, Castel V, Di Cataldo A, Munzer C, et al. Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience. J Clin Oncol (2009) 27:1014-9. doi:10.1200/JCO.2007.14.5839
9. Strother DR, London WB, Schmidt ML, Brodeur GM, Shimada H, Thorner P, et al. Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641. J Clin Oncol (2012) 30:1842-8. doi:10.1200/JCO.2011.37.9990
10. Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol (2009) 27:298-303. doi:10.1200/JCO.2008.16.6876
11. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol (2009) 27:289-97. doi:10.1200/JCO.2008.16.6785
12. Park JR, Bagatell R, London WB, Maris JM, Cohn SL, Mattay KM, et al. Children's Oncology Group's 2013 blueprint for research: neuroblastoma. Pediatr Blood Cancer (2013) 60:985-93. doi:10.1002/pbc.24433
13. Hakomori S. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol (2001) 491:369-402. doi:10.1007/978-1-4615-1267-7_24
14. Allende ML, Proia RL. Lubricating cell signaling pathways with gangliosides. Curr Opin Struct Biol (2002) 12:587-92. doi:10.1016/S0959-440X(02)00376-7
15. Todeschini AR, Hakomori SI. Functional role of glycosphingolipids and gangliosides in control of cell adhesion, motility, and growth, through glycosynaptic microdomains. Biochim Biophys Acta (2008) 1780:421-33. doi:10.1016/j.bbagen.2007.10.008
16. Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res (1996) 56:5309-18.
17. Ledeen RW, Yu RK. Gangliosides: structure, isolation, and analysis. Methods Enzymol (1982) 83:139-91. doi:10.1016/0076-6879(82)83012-7
18. van Echten G, Sandhoff K. Ganglioside metabolism. Enzymology, topology, and regulation. J Biol Chem (1993) 268:5341-4.
19. Dong L, Liu Y, Colberg-Poley AM, Kaucic K, Ladisch S. Induction of GM1a/GD1b synthase triggers complex ganglioside expression and alters neuroblastoma cell behavior a new tumor cell model of ganglioside function. Glycoconj J (2011) 28:137-47. doi:10.1007/s10719-011-9330-9
20. Kaucic K, Etue N, LaFleur B, Woods W, Ladisch S. Neuroblastomas of infancy exhibit a characteristic ganglioside pattern. Cancer (2001) 91:785-93. doi:10.1002/1097-0142(20010215)91:4<785::AID-CNCR1065>3.0.CO;2-R
21. Hettmer S, Malott C, Woods W, Ladisch S, Kaucic K. Biological stratification of human neuroblastoma by complex 'B' pathway ganglioside expression. Cancer Res (2003) 63:7270-6.
22. Schengrund CL, Repman MA, Shochat SJ. Ganglioside composition of human neuroblastomas. Correlation with prognosis. A Pediatric Oncology Group Study. Cancer (1985) 56:2640-6. doi:10.1002/1097-0142(19851201)56:11<2640::AID-CNCR2820561118>3.0.CO;2-W
23. Schengrund CL, Shochat SJ. Gangliosides in neuroblastomas. Neurochem Pathol (1988) 8:189-202.
24. Leskawa KC, Hogan EL. Quantitation of the in vitro neuroblastoma response to exogenous, purified gangliosides. J Neurosci Res (1985) 13:539-50. doi:10.1002/jnr.490130409
25. Mirkin BL, Clark SH, Zhang C. Inhibition of human neuroblastoma cell proliferation and EGF receptor phosphorylation by gangliosides GM1, GM3, GD1A and GT1B. Cell Prolif (2002) 35:105-15. doi:10.1046/j.1365-2184.2002.00228.x
26. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cisretinoic acid. Children's Cancer Group. N Engl J Med (1999) 341:1165-73. doi:10.1056/NEJM199910143411601
27. Hettmer S, McCarter R, Ladisch S, Kaucic K. Alterations in neuroblastoma ganglioside synthesis by induction of GD1b synthase by retinoic acid. Br J Cancer (2004) 91:389-97. doi:10.1038/sj.bjc.6601914
28. Wu ZL, Schwartz E, Seeger R, Ladisch S. Expression of GD2 ganglioside by untreated primary human neuroblastomas. Cancer Res (1986) 46:440-3.
29. Modak S, Cheung NK. Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest (2007) 25:67-77. doi:10.1080/07357900601130763
30. Cheresh DA, Pierschbacher MD, Herzig MA, Mujoo K. Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins. J Cell Biol (1986) 102:688-96. doi:10.1083/jcb.102.3.688
31. Li R, Ladisch S. Shedding of human neuroblastoma gangliosides. Biochim Biophys Acta (1991) 1083:57-64. doi:10.1016/0005-2760(91)90124-Z
32. Valentino L, Moss T, Olson E, Wang HJ, Elashoff R, Ladisch S. Shed tumor gangliosides and progression of human neuroblastoma. Blood (1990) 75:1564-7.
33. Olshefski R, Ladisch S. Intercellular transfer of shed tumor cell gangliosides. FEBS Lett (1996) 386:11-4. doi:10.1016/0014-5793(96)00392-4
34. Hakomori S. The glycosynapse. Proc Natl Acad Sci U S A (2002) 99:225-32. doi:10.1073/pnas.012540899
35. Kaucic K, Liu Y, Ladisch S. Modulation of growth factor signaling by gangliosides: positive or negative? Methods Enzymol (2006) 417:168-85. doi:10.1016/S0076-6879(06)17013-5
36. Liu Y, McCarthy J, Ladisch S. Membrane ganglioside enrichment lowers the threshold for vascular endothelial cell angiogenic signaling. Cancer Res (2006) 66:10408-14. doi:10.1158/0008-5472.CAN-06-1572
37. Liu Y, Wondimu A, Yan S, Bobb D, Ladisch S. Tumor gangliosides accelerate murine tumor angiogenesis. Angiogenesis (2013). doi:10.1007/s10456-013-9403-4
38. Potapenko M, Shurin GV, de León J. Gangliosides as immunomodulators. Adv Exp Med Biol (2007) 601:195-203. doi:10.1007/978-0-387-72005-0_20
39. Li R, Gage D, McKallip R, Ladisch S. Structural characterization and in vivo immunosuppressive activity of neuroblastoma GD2. Glycoconj J (1996) 13:385-9. doi:10.1007/BF00731471
40. Li R, Ladisch S. Abrogation of shedding of immunosuppressive neuroblastoma gangliosides. Cancer Res (1996) 56:4602-5.
41. Lee HC, Wondimu A, Liu Y, Ma JS, Radoja S, Ladisch S. Ganglioside inhibition of CD8+ T cell cytotoxicity: interference with lytic granule trafficking and exocytosis. J Immunol (2012) 189:3521-7. doi:10.4049/jimmunol.1201256
42. Nicoll G, Avril T, Lock K, Furukawa K, Bovin N, Crocker PR. Ganglioside GD3 expression on target cells can modulate NK cell cytotoxicity via siglec-7-dependent and -independent mechanisms. Eur J Immunol (2003) 33:1642-8. doi:10.1002/eji.200323693
43. Redlinger RE Jr, Mailliard RB, Barksdale EM Jr. Neuroblastoma and dendritic cell function. Semin Pediatr Surg (2004) 13:61-71. doi:10.1053/j.sempedsurg.2003.09.009
44. Shurin GV, Shurin MR, Bykovskaia S, Shogan J, Lotze MT, Barksdale EM Jr. Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res (2001) 61:363-9.
45. Walker SR, Redlinger RE Jr, Barksdale EM Jr. Neuroblastoma-induced inhibition of dendritic cell IL-12 production via abrogation of CD40 expression. J Pediatr Surg (2005) 40:244-9. doi:10.1016/j.jpedsurg.2004.09.050
46. Shen W, Stone K, Jales A, Leitenberg D, Ladisch S. Inhibition of TLR activation and up-regulation of IL-1R-associated kinase-M expression by exogenous gangliosides. J Immunol (2008) 180:4425-32. doi:10.4049/jimmunol.180.7.4425
47. Jales A, Falahati R, Mari E, Stemmy EJ, Shen W, Southammakosane C, et al. Ganglioside-exposed dendritic cells inhibit T-cell effector function by promoting regulatory cell activity. Immunology (2011) 132:134-43. doi:10.1111/j.1365-2567.2010.03348.x
48. Yoon KJ, Phelps DA, Bush RA, Remack JS, Billups CA, Khoury JD. ICAM-2 expression mediates a membrane-actin link, confers a nonmetastatic phenotype and reflects favorable tumor stage or histology in neuroblastoma. PLoS One (2008) 3:e3629. doi:10.1371/journal.pone.0003629
49. Feduska JM, Garcia PL, Brennan SB, Bu S, Council LN, Yoon KJ. N-glycosylation of ICAM-2 is required for ICAM-2-mediated complete suppression of metastatic potential of SK-N-AS neuroblastoma cells. BMC Cancer (2013) 13:261. doi:10.1186/1471-2407-13-261
50. Mossé YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature (2008) 455:930-5. doi:10.1038/nature07261
51. Passoni L, Longo L, Collini P, Coluccia AM, Bozzi F, Podda M, et al. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res (2009) 69:7338-46. doi:10.1158/0008-5472.CAN-08-4419
52. George RE, Sanda T, Hanna M, Fröhling S, Luther W, Zhang J, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature (2008) 455:975-8. doi:10.1038/nature07397
53. Del Grosso F, De Mariano M, Passoni L, Luksch R, Tonini GP, Longo L. Inhibition of N-linked glycosylation impairs ALK phosphorylation and disrupts pro-survival signaling in neuroblastoma cell lines. BMC Cancer (2011) 11:525. doi:10.1186/1471-2407-11-525
54. Bennett EP, Mandel U, Clausen H, Gerken TA, Fritz TA, Tabak LA. Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family. Glycobiology (2012) 22:736-56. doi:10.1093/glycob/cwr182
55. Dube DH, Bertozzi CR. Glycans in cancer and inflammation - potential for therapeutics and diagnostics. Nat Rev Drug Discov (2005) 4:477-88. doi:10.1038/nrd1751
56. Zhang S, Zhang HS, Cordon-Cardo C, Reuter VE, Singhal AK, Lloyd KO, et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int J Cancer (1997) 73:50-6. doi:10.1002/(SICI)1097-0215(19970926)73:1<42::AID-IJC8>3.0.CO;2-1
57. Berois N, Gattolliat CH, Barrios E, Capandeguy L, Douc-Rasy S, Valteau-Couanet D, et al. GALNT9 gene expression is a prognostic marker in neuroblastoma patients. Clin Chem (2013) 59:225-33. doi:10.1373/clinchem.2012.192328
58. Berois N, Blanc E, Ripoche H, Mergui X, Trajtenberg F, Cantais S, et al. ppGalNAc-T13: a new molecular marker of bone marrow involvement in neuroblastoma. Clin Chem (2006) 52:1701-12. doi:10.1373/clinchem.2006.067975
59. Ho WL, Che MI, Chou CH, Chang HH, Jeng YM, Hsu WM, et al. B3GNT3 expression suppresses cell migration and invasion and predicts favorable outcomes in neuroblastoma. Cancer Sci (2013) 104:1600-8. doi:10.1111/cas.12294
60. Finne J, Finne U, Deagostini-Bazin H, Goridis C. Occurrence of alpha 2-8 linked polysialosyl units in a neural cell adhesion molecule. Biochem Biophys Res Commun (1983) 112:482-7. doi:10.1016/0006-291X(83)91490-0
61. Santoni MJ, Goridis C, Fontecilla-Camps JC. Molecular modelling of the immunoglobulin-like domains of the neural cell adhesion molecule (NCAM): implications for the positioning of functionally important sugar side chains. J Neurosci Res (1988) 20:304-10. doi:10.1002/jnr.490200304
62. Mühlenhoff M, Eckhardt M, Gerardy-Schahn R. Polysialic acid: three-dimensional structure, biosynthesis and function. Curr Opin Struct Biol (1998) 8:558-64. doi:10.1016/S0959-440X(98)80144-9
63. Sadoul R, Hirn M, Deagostini-Bazin H, Rougon G, Goridis C. Adult and embryonic mouse neural cell adhesion molecules have different binding properties. Nature (1983) 304:347-9. doi:10.1038/304347a0
64. Johnson CP, Fujimoto I, Rutishauser U, Leckband DE. Direct evidence that neural cell adhesion molecule (NCAM) polysialylation increases intermembrane repulsion and abrogates adhesion. J Biol Chem (2005) 280:137-45. doi:10.1074/jbc.M410216200
65. Franceschini I, Angata K, Ong K, Hong A, Doherty P, Fukuda M. Polysialyltransferase ST8Sia II (STX) polysialylates all of the major isoforms of NCAM and facilitates neurite outgrowth. Glycobiology (2001) 11:231-9. doi:10.1093/glycob/11.3.231
66. Gascon E, Vutskits L, Kiss JK. Polysialic acid-neural cell adhesion molecule in brain plasticity: from synapses to integration of new neurons. Brain Res Rev (2007) 56:101-18. doi:10.1016/j.brainresrev.2007.05.014
67. Winter C, Pawel B, Seiser E, Zhao H, Raabe E, Wang Q, et al. Neural cell adhesion molecule (NCAM) isoform expression is associated with neuroblastoma differentiation status. Pediatr Blood Cancer (2008) 51:10-6. doi:10.1002/pbc.21475
68. Hildebrandt H, Muhlenhoff M, Weinhold B, Gerardy-Schahn R. Dissecting polysialic acid and NCAM functions in brain development. J Neurochem (2007) 103(Suppl 1):56-64. doi:10.1111/j.1471-4159.2007.04716.x
69. Rutishauser U, Landmesser L. Polysialic acid in the vertebrate nervous system: a promoter of plasticity in cell-cell interactions. Trends Neurosci (1996) 19:422-7. doi:10.1016/0166-2236(96)10041-2
70. Oltmann-Norden I, Galuska SP, Hildebrandt H, Geyer R, Gerardy-Schahn R, Geyer H, et al. Impact of the polysialyltransferases ST8SiaII and ST8SiaIV on polysialic acid synthesis during postnatal mouse brain development. J Biol Chem (2008) 283:1463-71. doi:10.1074/jbc.M708463200
71. Lipinski M, Hirsch MR, Deagostini-Bazin H, Yamada O, Tursz T, Goridis C. Characterization of neural cell adhesion molecules (NCAM) expressed by Ewing and neuroblastoma cell lines. Int J Cancer (1987) 40:81-6. doi:10.1002/ijc.2910400115
72. Figarella-Branger DF, Durbec PL, Rougon GN. Differential spectrum of expression of neural cell adhesion molecule isoforms and L1 adhesion molecules on human neuroectodermal tumors. Cancer Res (1990) 50:6364-70.
73. Tanaka F, Otake Y, Nakagawa T, Kawano Y, Miyahara R, Li M, et al. Expression of polysialic acid and STX, a human polysialyltransferase, is correlated with tumor progression in non-small cell lung cancer. Cancer Res (2000) 60:3072-80.
74. Glüer S, Schelp C, von Schweinitz D, Gerardy-Schahn R. Polysialylated neural cell adhesion molecule in childhood rhabdomyosarcoma. Pediatr Res (1998) 43:145-7. doi:10.1203/00006450-199804001-00861
75. Moolenaar CE, Muller EJ, Schol DJ, Figdor CG, Bock E, Bitter-Suermann D, et al. Expression of neural cell adhesion molecule-related sialoglycoprotein in small cell lung cancer and neuroblastoma cell lines H69 and CHP-212. Cancer Res (1990) 50:1102-6.
76. Scheidegger EP, Lackie PM, Papay J, Roth J. In vitro and in vivo growth of clonal sublines of human small cell lung carcinoma is modulated by polysialic acid of the neural cell adhesion molecule. Lab Invest (1994) 70:95-106.
77. Figarella-Branger D, Dubois C, Chauvin P, Devictor B, Gentet JC, Rougon G. Correlation between polysialic-neural cell adhesion molecule levels in CSF and medulloblastoma outcomes. J Clin Oncol (1996) 14:2066-72.
78. Glüer S, Schelp C, Madry N, von Schweinitz D, Eckhardt M, Gerardy-Schahn R. Serum polysialylated neural cell adhesion molecule in childhood neuroblastoma. Br J Cancer (1998) 78:106-10. doi:10.1038/bjc.1998.450
79. Glüer S, Schelp C, Gerardy-Schahn R, von Schweinitz D. Polysialylated neural cell adhesion molecule as a marker for differential diagnosis in pediatric tumors. J Pediatr Surg (1998) 33:1516-20. doi:10.1016/S0022-3468(98)90488-2
80. Daniel L, Durbec P, Gautherot E, Rouvier E, Rougon G, Figarella-Branger D. A nude mice model of human rhabdomyosarcoma lung metastases for evaluating the role of polysialic acids in the metastatic process. Oncogene (2001) 20:997-1004. doi:10.1038/sj.onc.1204176
81. Amoureux MC, Coulibaly B, Chinot O, Loundou A, Metellus P, Rougon G, et al. Polysialic acid neural cell adhesion molecule (PSA-NCAM) is an adverse prognosis factor in glioblastoma, and regulates olig2 expression in glioma cell lines. BMC Cancer (2010) 10:91. doi:10.1186/1471-2407-10-91
82. Seidenfaden R, Krauter A, Schertzinger F, Gerardy-Schahn R, Hildebrandt H. Polysialic acid directs tumor cell growth by controlling heterophilic neural cell adhesion molecule interactions. Mol Cell Biol (2003) 23:5908-18. doi:10.1128/MCB.23.16.5908-5918.2003
83. Hildebrandt H, Becker C, Glüer S, Rösner H, Gerardy-Schahn R, Rahmann H. Polysialic acid on the neural cell adhesion molecule correlates with expression of polysialyltransferases and promotes neuroblastoma cell growth. Cancer Res (1998) 58:779-84.
84. Eggers K, Werneburg S, Schertzinger A, Abeln M, Schiff M, Scharenberg MA, et al. Polysialic acid controls NCAM signals at cell-cell contacts to regulate focal adhesion independent from FGF receptor activity. J Cell Sci (2011) 124:3279-91. doi:10.1242/jcs.084863
85. Valentiner U, Mühlenhoff M, Lehmann U, Hildebrandt H, Schumacher U. Expression of the neural cell adhesion molecule and polysialic acid in human neuroblastoma cell lines. Int J Oncol (2011) 39:417-24. doi:10.3892/ijo.2011.1038
86. Glüer S, Zense M, Radtke E, von Schweinitz D. Polysialylated neural cell adhesion molecule in childhood ganglioneuroma and neuroblastoma of different histological grade and clinical stage. Langenbecks Arch Surg (1998) 383:340-4. doi:10.1007/s004230050145
87. Korja M, Jokilammi A, Salmi TT, Kalimo H, Pelliniemi TT, Isola J, et al. Absence of polysialylated NCAM is an unfavorable prognostic phenotype for advanced stage neuroblastoma. BMC Cancer (2009) 9:57. doi:10.1186/1471-2407-9-57
88. Angata K, Nakayama J, Fredette B, Chong K, Ranscht B, Fukuda M. Human STX polysialyltransferase forms the embryonic form of the neural cell adhesion molecule. Tissue-specific expression, neurite outgrowth, and chromosomal localization in comparison with another polysialyltransferase, PST. J Biol Chem (1997) 272:7182-90. doi:10.1074/jbc.272.11.7182
89. Thompson MG, Foley DA, Swartzentruber KG, Colley KJ. Sequences at the interface of the fifth immunoglobulin domain and first fibronectin type III repeat of the neural cell adhesion molecule are critical for its polysialylation. J Biol Chem (2011) 286:4525-34. doi:10.1074/jbc.M110.200386
90. Thompson MG, Foley DA, Colley KJ. The polysialyltransferases interact with sequences in two domains of the neural cell adhesion molecule to allow its polysialylation. J Biol Chem (2013) 288:7282-93. doi:10.1074/jbc.M112.438374
91. Kojima N, Tachida Y, Tsuji S. Two polysialic acid synthases, mouse ST8Sia II and IV, synthesize different degrees of polysialic acids on different substrate glycoproteins in mouse neuroblastoma Neuro2a cells. J Biochem (1997) 122:1265-73. doi:10.1093/oxfordjournals.jbchem.a021893
92. Scheidegger EP, Sternberg LR, Roth J, Lowe JB. A human STX cDNA confers polysialic acid expression in mammalian cells. J Biol Chem (1995) 270:22685-8. doi:10.1074/jbc.270.39.22685
93. Cheung IY, Vickers A, Cheung NK. Sialyltransferase STX (ST8SiaII): a novel molecular marker of metastatic neuroblastoma. Int J Cancer (2006) 119:152-6. doi:10.1002/ijc.21789
94. Seidenfaden R, Gerardy-Schahn R, Hildebrandt H. Control of NCAM polysialylation by the differential expression of polysialyltransferases ST8SiaII and ST8SiaIV. Eur J Cell Biol (2000) 79:680-8. doi:10.1078/0171-9335-00093
95. Falconer RA, Errington RJ, Shnyder SD, Smith PJ, Patterson LH. Polysialyltransferase: a new target in metastatic cancer. Curr Cancer Drug Targets (2012) 12:925-39. doi:10.2174/156800912803251225
96. Al-Saraireh YM, Sutherland M, Springett BR, Freiberger F, Ribeiro Morais G, Loadman PM, et al. Pharmacological inhibition of polysialyltransferase ST8SiaII modulates tumour cell migration. PLoS One (2013) 8:e73366. doi:10.1371/journal.pone.0073366
97. Seifert A, Glanz D, Glaubitz N, Horstkorte R, Bork K. Polysialylation of the neural cell adhesion molecule: interfering with polysialylation and migration in neuroblastoma cells. Arch Biochem Biophys (2012) 524:56-63. doi:10.1016/j.abb.2012.04.011
98. Rabinovich GA, Croci DO. Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer. Immunity (2012) 36:322-35. doi:10.1016/j.immuni.2012.03.004
99. Yang RY, Rabinovich G, Liu FT. Galectins: structure, function and therapeutic potential. Expert Rev Mol Med (2008) 10:e17. doi:10.1017/S1462399408000719
100. Liu FT, Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer (2005) 5:29-41. doi:10.1038/nrc1527
101. Ito K, Stannard K, Gabutero E, Clark AM, Neo SY, Onturk S, et al. Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment. Cancer Metastasis Rev (2012) 31:763-78. doi:10.1007/s10555-012-9388-2
102. Croci DO, Cerliani JP, Dalotto-Moreno T, Méndez-Huergo SP, Mascanfroni ID, Dergan-Dylon S, et al. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell (2014) 156:744-58. doi:10.1016/j.cell.2014.01.043
103. Juszczynski P, Ouyang J, Monti S, Rodig SJ, Takeyama K, Abramson J, et al. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci U S A (2007) 104:13134-9. doi:10.1073/pnas.0706017104
104. Banh A, Zhang J, Cao H, Bouley DM, Kwok S, Kong C, et al. Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis. Cancer Res (2011) 71:4423-31. doi:10.1158/0008-5472.CAN-10-4157
105. Kuo PL, Hung JY, Huang SK, Chou SH, Cheng DE, Jong YJ, et al. Lung cancer-derived galectin-1 mediates dendritic cell anergy through inhibitor of DNA binding 3/IL-10 signaling pathway. J Immunol (2011) 186:1521-30. doi:10.4049/jimmunol.1002940
106. Cimmino F, Schulte JH, Zollo M, Koster J, Versteeg R, Iolascon A, et al. Galectin-1 is a major effector of TrkB-mediated neuroblastoma aggressiveness. Oncogene (2009) 28:2015-23. doi:10.1038/onc.2009.70
107. Soldati R, Berger E, Zenclussen AC, Jorch G, Lode HN, Salatino M, et al. Neuroblastoma triggers an immunoevasive program involving galectin-1-dependent modulation of T cell and dendritic cell compartments. Int J Cancer (2012) 131:1131-41. doi:10.1002/ijc.26498
108. Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A, et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; a potential mechanism of tumor immune privilege. Cancer Cell (2004) 5:241-51. doi:10.1016/S1535-6108(04)00024-8
109. Dalotto-Moreno T, Croci DO, Cerliani JP, Martinez-Allo VC, Dergan-Dylon S, Méndez-Huergo SP, et al. Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease. Cancer Res (2013) 73:1107-17. doi:10.1158/0008-5472.CAN-12-2418
110. Ambros PF, Mehes G, Ambros IM, Ladenstein R. Disseminated tumor cells in the bone marrow - chances and consequences of microscopical detection methods. Cancer Lett (2003) 197:29-34. doi:10.1016/S0304-3835(03)00078-8
111. Hoon DS, Kuo CT, Wen S, Wang H, Metelitsa L, Reynolds CP, et al. Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow. Am J Pathol (2001) 159:493-500. doi:10.1016/S0002-9440(10)61721-X
112. Meany DL, Chan DW. Aberrant glycosylation associated with enzymes as cancer biomarkers. Clin Proteomics (2011) 8:7. doi:10.1186/1559-0275-8-7
113. Cheung NK, Von Hoff DD, Strandjord SE, Coccia PF. Detection of neuroblastoma cells in bone marrow using GD2 specific monoclonal antibodies. J Clin Oncol (1986) 4:363-9.
114. Lo Piccolo MS, Cheung NKV, Cheung IY. GD2 synthase: a new molecular marker for detecting neuroblastoma. Cancer (2001) 92:924-31. doi:10.1002/1097-0142(20010815)92:4<924::AID-CNCR1402>3.0.CO;2-O
115. Cheung IY, Lo Piccolo MS, Kushner BH, Cheung NK. Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma. J Clin Oncol (2003) 21:3853-8. doi:10.1200/JCO.2003.11.077
116. Träger C, Vernby A, Kullman A, Ora I, Kogner P, Kågedal B. mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis. Int J Cancer (2008) 123:2849-55. doi:10.1002/ijc.23846
117. Beiske K, Burchill SA, Cheung IY, Hiyama E, Seeger RC, Cohn SL, et al. Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force. Br J Cancer (2009) 100:1627-37. doi:10.1038/sj.bjc.6605029
118. Dennis JW, Laferte S, Waghorne C, Breitman ML, Kerbel RS. Beta 1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science (1987) 236:582-5. doi:10.1126/science.2953071
119. Fernandes B, Sagman U, Auger M, Demetrio M, Dennis JW. Beta 1-6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia. Cancer Res (1991) 51:718-23.
120. Seelentag WK, Li WP, Schmitz SF, Metzger U, Aeberhard P, Heitz PU, et al. Prognostic value of beta1,6-branched oligosaccharides in human colorectal carcinoma. Cancer Res (1998) 58:5559-64.
121. Murata K, Miyoshi E, Kameyama M, Ishikawa O, Kabuto T, Sasaki Y, et al. Expression of N-acetylglucosaminyltransferase V in colorectal cancer correlates with metastasis and poor prognosis. Clin Cancer Res (2000) 6:1772-7.
122. Dosaka-Akita H, Miyoshi E, Suzuki O, Itoh T, Katoh H, Taniguchi N. Expression of N-acetylglucosaminyltransferase V is associated with prognosis and histology in nonsmall cell lung cancers. Clin Cancer Res (2004) 10:1773-9. doi:10.1158/1078-0432.CCR-1047-3
123. Inamori K, Gu J, Ohira M, Kawasaki A, Nakamura Y, Nakagawa T, et al. High expression of N-acetylglucosaminyltransferase V in favorable neuroblastomas: involvement of its effect on apoptosis. FEBS Lett (2006) 580:627-32. doi:10.1016/j.febslet.2005.12.089
124. Cheung IY, Feng Y, Gerald W, Cheung NK. Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma. Clin Cancer Res (2008) 14:7020-7. doi:10.1158/1078-0432.CCR-08-0541
125. Takita J, Ishii M, Tsutsumi S, Tanaka Y, Kato K, Toyoda Y, et al. Gene expression profiling and identification of novel prognostic marker genes in neuroblastoma. Genes Chromosomes Cancer (2004) 40:120-32. doi:10.1002/gcc.20021
126. Fischer M, Oberthuer A, Brors B, Kahlert Y, Skowron M, Voth H, et al. Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome. Clin Cancer Res (2006) 12:5118-28. doi:10.1158/1078-0432.CCR-06-0985
127. Ferrandis E, Da Silva J, Riou G, Bénard J. Coactivation of the MDR1 and MYCN in human neuroblastoma during the metastatic process in the nude mouse. Cancer Res (1994) 54:2256-61.
128. Blanc E, Goldschneider D, Ferrandis E, Barrois M, Le Roux G, Leonce S, et al. MYCN enhances P-gp/MDR1 gene expression in the human metastatic neuroblastoma IGR-N-91 model. Am J Pathol (2003) 163:321-31. doi:10.1016/S0002-9440(10)63656-5
129. Zhang Y, Iwasaki H, Wang H, Kudo T, Kalka TB, Hennet T, et al. Cloning and characterization of a new human UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase, designated pp-GalNAc-T13, that is specifically expressed in neurons and synthesizes GalNAc alpha-serine/threonine antigen. J Biol Chem (2003) 278:573-84. doi:10.1074/jbc.M203094200
130. Toba S, Tenno M, Konishi M, Mikami T, Itoh N, Kurosaka A. Brain-specific expression of a novel human UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase (GalNAc-T9). Biochim Biophys Acta (2000) 1493:264-8. doi:10.1016/S0167-4781(00)00180-9
131. Piacentini M, Piredda L, Starace DT, Annicchiarico-Petruzzelli M, Mattei M, Oliverio S, et al. Differential growth of N- and S-type human neuroblastoma cells xenografted into SCID mice. Correlation with apoptosis. J Pathol (1996) 180:415-22. doi:10.1002/(SICI)1096-9896(199612)180:4<415::AID-PATH684>3.0.CO;2-A
132. Mitoma J, Petryniak B, Hiraoka N, Yeh JC, Lowe JB, Fukuda M. Extended core 1 and core 2 branched O-glycans differentially modulate sialyl Lewis X-type L-selectin ligand activity. J Biol Chem (2003) 278:9953-61. doi:10.1074/jbc.M212756200
133. Yago T, Fu J, McDaniel JM, Miner JJ, McEver RP, Xia L. Core 1-derived O-glycans are essential E-selectin ligands on neutrophils. Proc Natl Acad Sci U S A (2010) 107:9204-9. doi:10.1073/pnas.1003110107
134. Köhler S, Ullrich S, Richter U, Schumacher U. E-/P-selectins and colon carcinoma metastasis: first in vivo evidence for their crucial role in a clinically relevant model of spontaneous metastasis formation in the lung. Br J Cancer (2010) 102:602-9. doi:10.1038/sj.bjc.6605492
135. Gakhar G, Navarro VN, Jurish M, Lee GY, Tagawa ST, Akhtar NH, et al. Circulating tumor cells from prostate cancer patients interact with E-selectin under physiologic blood flow. PLoS One (2013) 8:e85143. doi:10.1371/journal.pone.0085143
136. Sato T, Gotoh M, Kiyohara K, Kameyama A, Kubota T, Kikuchi N, et al. Molecular cloning and characterization of a novel human β1,4-N-acetylgalactosaminyltransferase, β4GalNAc-T3, responsible for the synthesis of N,N′-diacetyllactosediamine, galNAc β1-4GlcNAc. J Biol Chem (2003) 278:47534-44. doi:10.1074/jbc.M308857200
137. Kawar ZS, Haslam SM, Morris HR, Dell A, Cummings RD. Novel poly-GalNAcbeta1-4GlcNAc (LacdiNAc) and fucosylated poly-LacdiNAc N-glycans from mammalian cells expressing beta1,4-N-acetylgalactosaminyltransferase and alpha1,3-fucosyltransferase. J Biol Chem (2005) 280:12810-919. doi:10.1074/jbc.M414273200
138. Fiete D, Beranek M, Baenziger JU. Peptide-specific transfer of N-acetylgalactosamine to O-linked glycans by the glycosyltransferases β1,4-N-acetylgalactosaminyl transferase 3 (β4GalNAc-T3) and β4GalNAc-T4. J Biol Chem (2012) 287:29204-12. doi:10.1074/jbc.M112.371880
139. Ikehara Y, Sato T, Niwa T, Nakamura S, Gotoh M, Ikehara SK, et al. Apical Golgi localization of N,N'-diacetyllactosediamine synthase, beta4GalNAc-T3, is responsible for LacdiNAc expression on gastric mucosa. Glycobiology (2006) 16:777-85. doi:10.1093/glycob/cwl005
140. Huang J, Liang JT, Huang HC, Shen TL, Chen HY, Lin NY, et al. Beta1,4-N-acetylgalactosaminyltransferase III enhances malignant phenotypes of colon cancer cells. Mol Cancer Res (2007) 5:543-52. doi:10.1158/1541-7786.MCR-06-0431
141. Chen CH, Wang SH, Liu CH, Wu YL, Wang WJ, Huang J, et al. β-1,4-galactosyltransferase III suppresses β1 integrin mediated invasive phenotypes and negatively correlates with metastasis in colorectal cancer. Carcinogenesis (2014). doi:10.1093/carcin/bgu007
142. Hsu WM, Che MI, Liao YF, Chang HH, Chen CH, Huang YM, et al. B4GALNT3 expression predicts a favorable prognosis and suppresses cell migration and invasion via β1 integrin signaling in neuroblastoma. Am J Pathol (2011) 179:1394-404. doi:10.1016/j.ajpath.2011.05.025
143. Chang HH, Chen CH, Chou CH, Liao YF, Huang MJ, Chen YH, et al. β-1,4-galactosyltransferase III enhances invasive phenotypes via β1-integrin and predicts poor prognosis in neuroblastoma. Clin Cancer Res (2013) 19:1705-16. doi:10.1158/1078-0432.CCR-12-2367
144. De Bernardi B, Gerrard M, Boni L, Rubie H, Cañete A, Di Cataldo A, et al. Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J Clin Oncol (2009) 27:1034-40. doi:10.1200/JCO.2008.17.5877
145. Modak S, Cheung NK. Neuroblastoma: therapeutic strategies for a clinical enigma. Cancer Treat Rev (2010) 36:307-17. doi:10.1016/j.ctrv.2010.02.006
146. Barone G, Anderson J, Pearson AD, Petrie K, Chesler L. New strategies in neuroblastoma: therapeutic targeting of MYCN and ALK. Clin Cancer Res (2013) 19:5814-21. doi:10.1158/1078-0432.CCR-13-0680
147. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res (2013) 19:5300-9. doi:10.1158/1078-0432.CCR-13-0143
148. Baxevanis CN, Papamichail M, Perez SA. Therapeutic cancer vaccines: a long and winding road to success. Expert Rev Vaccines (2014) 13:131-44. doi:10.1586/14760584.2014.852961
149. Darcy PK, Neeson P, Yong CS, Kershaw MH. Manipulating immune cells for adoptive immunotherapy of cancer. Curr Opin Immunol (2014) 27C:46-52. doi:10.1016/j.coi.2014.01.008
150. Kyi C, Postow MA. Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett (2014) 588:368-76. doi:10.1016/j.febslet.2013.10.015
151. Zigler M, Shir A, Levitzki A. Targeted cancer immunotherapy. Curr Opin Pharmacol (2013) 13:504-10. doi:10.1016/j.coph.2013.04.003
152. Freire T, Osinaga E. The sweet side of tumor immunotherapy. Immunotherapy (2012) 4:719-34. doi:10.2217/imt.12.58
153. Cheung NK, Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer (2013) 13:397-411. doi:10.1038/nrc3526
154. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res (2009) 15:5323-37. doi:10.1158/1078-0432.CCR-09-0737
155. Matthay KK, George RE, Yu AL. Promising therapeutic targets in neuroblastoma. Clin Cancer Res (2012) 18:2740-53. doi:10.1158/1078-0432.CCR-11-1939
156. Parsons K, Bernhardt B, Strickland B. Targeted immunotherapy for high-risk neuroblastoma - the role of monoclonal antibodies. Ann Pharmacother (2013) 47:210-8. doi:10.1345/aph.1R353
157. Ahmed M, Cheung NK. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. FEBS Lett (2014) 588:288-97. doi:10.1016/j.febslet.2013.11.030
158. Cheung NK, Saarinen UM, Neely JE, Landmeier B, Donovan D, Coccia PF. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res (1985) 45:2642-9.
159. Cheung NK, Lazarus H, Miraldi FD, Abramowsky CR, Kallick S, Saarinen UM, et al. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol (1987) 5:1430-40.
160. Kushner BH, Cheung NK. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood (1989) 73:1936-41.
161. Kushner BH, Cheung NK. Clinically effective monoclonal antibody 3F8 mediates nonoxidative lysis of human neuroectodermal tumor cells by polymorphonuclear leukocytes. Cancer Res (1991) 51:4865-70.
162. Kushner BH, Cheung NK. Absolute requirement of CD11/CD18 adhesion molecules, FcRII and the phosphatidylinositol-linked FcRIII for monoclonal antibody-mediated neutrophil antihuman tumor cytotoxicity. Blood (1992) 79:1484-90.
163. Cheung NK, Walter EI, Smith-Mensah WH, Ratnoff WD, Tykocinski ML, Medof ME. Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J Clin Invest (1988) 81:1122-8. doi:10.1172/JCI113426
164. Chen S, Caragine T, Cheung NK, Tomlinson S. CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma. Cancer Res (2000) 60:3013-8.
165. Hank JA, Robinson RR, Surfus J, Mueller BM, Reisfeld RA, Cheung NK, et al. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res (1990) 50:5234-9.
166. Barker E, Reisfeld RA. A mechanism for neutrophil-mediated lysis of human neuroblastoma cells. Cancer Res (1993) 53:362-7.
167. Cheung NK, Cheung IY, Kushner BH, Ostrovnaya I, Chamberlain E, Kramer K, et al. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol (2012) 30:3264-70. doi:10.1200/JCO.2011.41.3807
168. Cheung NK, Guo H, Hu J, Tassev DV, Cheung IY. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology (2012) 1:477-86. doi:10.4161/onci.19864
169. Mujoo K, Kipps TJ, Yang HM, Cheresh DA, Wargalla U, Sander DJ, et al. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res (1989) 49:2857-61.
170. Gillies SD, Lo KM, Wesolowski J. High-level expression of chimeric antibodies using adapted cDNA variable region cassettes. J Immunol Methods (1989) 125:191-202. doi:10.1016/0022-1759(89)90093-8
171. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med (2010) 363:1324-34. doi:10.1056/NEJMoa0911123
172. Yang RK, Kalogriopoulos NA, Rakhmilevich AL, Ranheim EA, Seo S, Kim K, et al. Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention. J Immunol (2012) 189:2656-64. doi:10.4049/jimmunol.1200934
173. Tur MK, Sasse S, Stöcker M, Djabelkhir K, Huhn M, Matthey B, et al. An anti-GD2 single chain Fv selected by phage display and fused to Pseudomonas exotoxin A develops specific cytotoxic activity against neuroblastoma derived cell lines. Int J Mol Med (2001) 8:579-84. doi:10.3892/ijmm.8.5.579
174. Lode HN, Reisfeld RA, Handgretinger R, Nicolaou KC, Gaedicke G, Wrasidlo W. Targeted therapy with a novel enediyene antibiotic calicheamicin theta(I)1 effectively suppresses growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma. Cancer Res (1998) 58:2925-8.
175. Vavere AL, Butch ER, Dearling JL, Packard AB, Navid F, Shulkin BL, et al. 64Cu-p-NH2-Bn-DOTA-hu14.18K322A, a PET radiotracer targeting neuroblastoma and melanoma. J Nucl Med (2012) 53:1772-8. doi:10.2967/jnumed.112.104208
176. Tivnan A, Orr WS, Gubala V, Nooney R, Williams DE, McDonagh C, et al. Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS One (2012) 7:e38129. doi:10.1371/journal.pone.0038129
177. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer (2003) 3:35-45. doi:10.1038/nrc971
178. Cheadle EJ, Gornall H, Baldan V, Hanson V, Hawkins RE, Gilham DE. CAR T cells: driving the road from the laboratory to the clinic. Immunol Rev (2014) 257:91-106. doi:10.1111/imr.12126
179. Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev (2014) 257:107-26. doi:10.1111/imr.12131
180. Rossig C, Bollard C, Nuchtern J, Merchant D, Brenner M. Targeting of GD2-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int J Cancer (2001) 94:228-36. doi:10.1002/ijc.1457
181. Yun C, Nolan K, Beecham E, Reisfeld R, Junghans R. Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. Neoplasia (2000) 2:449-59. doi:10.1038/sj.neo.7900108
182. Yvon E, Del Vecchio M, Savoldo B, Hoyos V, Dutour A, Anichini A, et al. Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin Cancer Res (2009) 15:5852-60. doi:10.1158/1078-0432.CCR-08-3163
183. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med (2008) 14:1264-70. doi:10.1038/nm.1882
184. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood (2011) 118:6050-6. doi:10.1182/blood-2011-05-354449